Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 2:57 am
Author: Getaka|Social: XLinkedIn

Glaxosmithkline Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹1,512.23Overvalued by 35.07%vs CMP ₹2,329.00

P/E (39.2) × ROE (46.9%) × BV (₹101.00) × DY (1.80%)

₹652.42Overvalued by 71.99%vs CMP ₹2,329.00
MoS: -257% (Negative)Confidence: 68/100 (Moderate)Models: All 9: Overvalued
ModelCategoryValueWeightSignal
PE-ROEEarnings₹1,366.4822%Over (-41.3%)
Graham NumberEarnings₹370.0916%Over (-84.1%)
Earnings PowerEarnings₹322.6811%Over (-86.1%)
DCFCash Flow₹592.1913%Over (-74.6%)
Net Asset ValueAssets₹100.767%Over (-95.7%)
EV/EBITDAEnterprise₹880.419%Over (-62.2%)
Earnings YieldEarnings₹602.707%Over (-74.1%)
ROCE CapitalReturns₹306.939%Over (-86.8%)
Revenue MultipleRevenue₹331.935%Over (-85.7%)
Consensus (9 models)₹652.42100%Overvalued
Key Drivers: Wide model spread (₹101–₹1,366) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: -9.6%

*Investments are subject to market risks

Investment Snapshot

77
Glaxosmithkline Pharmaceuticals Ltd scores 77/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health92/100 · Strong
ROCE 63.2% ExcellentROE 46.9% ExcellentD/E 0.00 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.11% (6mo) Slight increasePromoter holding at 75.0% Stable
Earnings Quality75/100 · Strong
OPM expanding (24% → 29%) ImprovingWorking capital: -99 days (improving) Efficient
Quarterly Momentum70/100 · Strong
Revenue (4Q): 4% YoY FlatProfit (4Q): +42% YoY Strong
Industry Rank70/100 · Strong
P/E 39.2 vs industry 53.8 In-lineROCE 63.2% vs industry 16.4% Above peersROE 46.9% vs industry 15.2% Above peers3Y sales CAGR: 5% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 2:57 am

Market Cap 39,458 Cr.
Current Price 2,329
Intrinsic Value₹652.42
High / Low 3,516/2,218
Stock P/E39.2
Book Value 101
Dividend Yield1.80 %
ROCE63.2 %
ROE46.9 %
Face Value 10.0
PEG Ratio-4.07

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Glaxosmithkline Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Glaxosmithkline Pharmaceuticals Ltd 39,458 Cr. 2,329 3,516/2,21839.2 1011.80 %63.2 %46.9 % 10.0
Ipca Laboratories Ltd 38,264 Cr. 1,508 1,624/1,16836.2 2930.27 %14.7 %12.8 % 1.00
Ajanta Pharma Ltd 35,192 Cr. 2,817 3,228/2,02234.7 3450.99 %32.4 %24.9 % 2.00
J B Chemicals & Pharmaceuticals Ltd 32,253 Cr. 2,009 2,195/1,30342.8 2430.77 %25.8 %20.1 % 1.00
Gland Pharma Ltd 28,107 Cr. 1,706 2,131/1,20023.7 6101.06 %15.8 %11.6 % 1.00
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Glaxosmithkline Pharmaceuticals Ltd

Quarterly Result

MetricSep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
Sales 9178027877629578059308151,011949974805980
Expenses 660574618618668587673584689658641554644
Operating Profit 257229170144289218257231322292333251336
OPM % 28%29%22%19%30%27%28%28%32%31%34%31%34%
Other Income 2212385428-13532363935414436
Interest 0010001000101
Depreciation 16161716181718161719151617
Profit before tax 26222419018129965271249344308359279354
Tax % 26%27%30%27%27%30%28%27%27%25%27%27%27%
Net Profit 19316513313221846194182252230263205257
EPS in Rs 11.429.717.887.8112.842.7011.4810.7614.9113.5715.5212.1015.20

Last Updated: January 1, 2026, 4:16 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: April 2, 2026, 4:00 am

MetricDec 2013Mar 2015n n n 15mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 2,5633,3052,8382,9082,8713,1283,2242,9263,2783,2523,4543,7493,801
Expenses 2,0342,6722,3602,4892,3632,5272,5672,3272,5162,4472,5452,5702,509
Operating Profit 5286334784205086016575987628049091,1791,291
OPM % 21%19%17%14%18%19%20%20%23%25%26%31%34%
Other Income 20314912511970131-26291,401103-21149171
Interest 0000016422213
Depreciation 20252527384983796866706768
Profit before tax 7117565785115406833065252,0938398161,2601,391
Tax % 32%37%35%34%35%35%70%32%19%27%28%26%
Net Profit 482476376337351445933581,6956115909281,021
EPS in Rs 28.4328.1222.2019.8820.7026.295.5021.14100.0436.0534.8354.7560.27
Dividend Payout % 88%111%113%75%85%76%727%142%90%89%92%99%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-10.37%4.15%26.78%-79.10%284.95%373.46%-63.95%-3.44%57.29%
Change in YoY Net Profit Growth (%)0.00%14.53%22.63%-105.88%364.05%88.52%-437.42%60.52%60.73%

Glaxosmithkline Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:1%
5 Years:3%
3 Years:5%
TTM:7%
Compounded Profit Growth
10 Years:6%
5 Years:35%
3 Years:-20%
TTM:23%
Stock Price CAGR
10 Years:6%
5 Years:13%
3 Years:26%
1 Year:1%
Return on Equity
10 Years:30%
5 Years:45%
3 Years:36%
Last Year:47%

Last Updated: September 5, 2025, 4:50 am

Balance Sheet

Last Updated: January 7, 2026, 3:43 pm

MonthDec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 8585858585169169169169169169169169
Reserves 1,9051,7442,0991,9221,9731,9701,6511,3092,4941,5721,6081,7821,538
Borrowings 4322110352016191036
Other Liabilities 1,1361,3848699951,8891,7711,3151,6021,9501,5701,7602,1471,922
Total Liabilities 3,1303,2163,0553,0043,9473,9113,1363,1154,6333,3273,5574,1083,665
Fixed Assets 100123204258325432758387331330321284291
CWIP 621152686059231,003120133020141417
Investments 1006000003665188131,1181,313
Other Assets 2,9582,9772,5772,1402,7002,4772,2572,7153,9072,4582,4082,6922,044
Total Assets 3,1303,2163,0553,0043,9473,9113,1363,1154,6333,3273,5574,1083,665

Reserves and Borrowings Chart

Cash Flow

MonthDec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 2813381392344734094905788114845821,290
Cash from Investing Activity + 189180499301-104-153-57418-4068089-46
Cash from Financing Activity + -494-497-638-511-307-358-428-696-524-1,543-562-769
Net Cash Flow -2421-02462-1026300-119-25129475
Free Cash Flow 251175-69-246391663365362,3714515731,273
CFO/OP 99%93%72%94%133%101%103%121%122%93%92%116%

Free Cash Flow

MonthDec 2013Mar 2015n n n 15mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow524.00633.00476.00418.00507.00600.00657.00563.00742.00788.00890.00-9.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthDec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 141116211914112723222328
Inventory Days 10991156111147131135159144131144126
Days Payable 90749773149109100135156122171186
Cash Conversion Cycle 33277560173646501131-4-31
Working Capital Days -45-48267-90-72-38-39-94-57-64-99
ROCE %34%42%29%22%26%31%33%38%37%36%51%63%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%75.00%
FIIs 2.28%2.41%2.50%2.93%3.48%4.02%4.36%4.50%4.52%4.89%4.79%4.63%
DIIs 10.31%10.25%10.01%8.64%7.90%7.51%7.34%7.30%7.79%7.71%7.75%7.70%
Government 0.00%0.00%0.01%0.01%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Public 12.43%12.35%12.48%13.42%13.62%13.48%13.30%13.21%12.69%12.41%12.45%12.67%
No. of Shareholders 1,20,4151,19,0321,15,2681,14,6631,18,9941,18,5151,19,2281,19,6251,21,8851,23,6291,22,9041,22,460

Shareholding Pattern Chart

No. of Shareholders

Glaxosmithkline Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
SBI Midcap Fund 1,200,000 1.29 288.19N/AN/AN/A
Kotak Large & Midcap Fund 1,100,000 0.88 264.18N/AN/AN/A
Nippon India Pharma Fund 913,226 2.78 219.32853,9072025-12-08 01:23:056.95%
Nippon India Growth Mid Cap Fund 559,000 0.32 134.25N/AN/AN/A
SBI Dividend Yield Fund 450,000 1.21 108.07N/AN/AN/A
Kotak Flexicap Fund 399,331 0.17 95.9N/AN/AN/A
Bajaj Finserv Flexi Cap Fund 318,621 1.23 76.52290,0802026-02-23 01:13:059.84%
Aditya Birla Sun Life MNC Fund 260,835 1.83 62.64N/AN/AN/A
Bandhan ELSS Tax Saver Fund 255,000 0.87 61.24245,0002026-02-23 01:13:054.08%
Aditya Birla Sun Life Multi-Cap Fund 227,787 0.84 54.71N/AN/AN/A

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 54.5241.1436.0899.2931.35
Diluted EPS (Rs.) 54.7634.8336.05100.0421.14
Cash EPS (Rs.) 58.7038.9439.93104.0625.78
Book Value[Excl.RevalReserv]/Share (Rs.) 115.19104.93102.79157.1987.26
Book Value[Incl.RevalReserv]/Share (Rs.) 115.19104.93102.79157.1987.26
Revenue From Operations / Share (Rs.) 221.32203.87191.95193.50172.70
PBDIT / Share (Rs.) 78.1160.8853.4249.4541.84
PBIT / Share (Rs.) 74.1756.7649.5445.4237.20
PBT / Share (Rs.) 74.3748.1849.3745.9926.80
Net Profit / Share (Rs.) 54.7634.8336.05100.0421.14
NP After MI And SOA / Share (Rs.) 54.9135.0736.41100.0421.14
PBDIT Margin (%) 35.2929.8627.8225.5524.22
PBIT Margin (%) 33.5127.8425.8023.4721.53
PBT Margin (%) 33.6023.6325.7223.7615.51
Net Profit Margin (%) 24.7417.0818.7851.6912.24
NP After MI And SOA Margin (%) 24.8117.2018.9651.6912.24
Return on Networth / Equity (%) 47.6733.4235.4163.6424.22
Return on Capital Employeed (%) 57.0347.3341.9526.2135.80
Return On Assets (%) 22.6416.7018.5336.5711.49
Asset Turnover Ratio (%) 0.971.000.800.830.93
Current Ratio (X) 1.791.841.882.181.63
Quick Ratio (X) 1.541.491.531.871.22
Inventory Turnover Ratio (X) 7.451.110.811.040.89
Dividend Payout Ratio (NP) (%) 80.1291.24247.2129.98189.20
Dividend Payout Ratio (CP) (%) 74.7681.66223.3928.82155.15
Earning Retention Ratio (%) 19.888.76-147.2170.02-89.20
Cash Earning Retention Ratio (%) 25.2418.34-123.3971.18-55.15
Interest Coverage Ratio (X) 1007.30573.35499.36419.65200.69
Interest Coverage Ratio (Post Tax) (X) 703.51408.84336.84185.96131.22
Enterprise Value (Cr.) 47339.6731854.0621275.9725686.8623243.30
EV / Net Operating Revenue (X) 12.639.226.547.847.94
EV / EBITDA (X) 35.7730.8923.5130.6732.80
MarketCap / Net Operating Revenue (X) 13.009.536.908.598.34
Retention Ratios (%) 19.878.75-147.2170.01-89.20
Price / BV (X) 24.9818.5212.8810.5816.51
Price / Net Operating Revenue (X) 13.009.536.908.598.34
EarningsYield 0.010.010.020.060.01

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 3723.49 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsGSK House, Dr. Annie Besant Road, Mumbai Maharashtra 400030Contact not found
Management
NamePosition Held
Ms. R S KarnadChairperson
Mr. B AkshikarManaging Director
Mr. J ChandyWholeTime Director & CFO
Mr. S WilliamsNon Executive Director
Mr. M AnandIndependent Director
Mr. P R SomasundaramIndependent Director
Dr. A WadhawanIndependent Director
Dr.(Ms.) S MaheshwariIndependent Director

FAQ

What is the intrinsic value of Glaxosmithkline Pharmaceuticals Ltd and is it undervalued?

As of 20 April 2026, Glaxosmithkline Pharmaceuticals Ltd's intrinsic value is ₹652.42, which is 71.99% lower than the current market price of ₹2,329.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (46.9 %), book value (₹101), dividend yield (1.80 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Glaxosmithkline Pharmaceuticals Ltd?

Glaxosmithkline Pharmaceuticals Ltd is trading at ₹2,329.00 as of 20 April 2026, with a FY2026-2027 high of ₹3,516 and low of ₹2,218. The stock is currently near its 52-week low. Market cap stands at ₹39,458 Cr..

How does Glaxosmithkline Pharmaceuticals Ltd's P/E ratio compare to its industry?

Glaxosmithkline Pharmaceuticals Ltd has a P/E ratio of 39.2, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Glaxosmithkline Pharmaceuticals Ltd financially healthy?

Key indicators for Glaxosmithkline Pharmaceuticals Ltd: ROCE of 63.2 % indicates efficient capital utilization; ROE of 46.9 % shows strong shareholder returns. Dividend yield is 1.80 %.

Is Glaxosmithkline Pharmaceuticals Ltd profitable and how is the profit trend?

Glaxosmithkline Pharmaceuticals Ltd reported a net profit of ₹928 Cr in Mar 2025 on revenue of ₹3,749 Cr. Compared to ₹1,695 Cr in Mar 2022, the net profit shows a declining trend.

Does Glaxosmithkline Pharmaceuticals Ltd pay dividends?

Glaxosmithkline Pharmaceuticals Ltd has a dividend yield of 1.80 % at the current price of ₹2,329.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Glaxosmithkline Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports